XENE
Xenon Pharmaceuticals Inc.·Healthcare
59.70
2.174%(+1.27)
Market ClosedLast Updated: — ET
52W L: $28.1952W H: $63.95
XENE NEWS
globenewswire.com
3d ago
Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the second quarter of 2026.
globenewswire.com
Apr 7
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.
defenseworld.net
Apr 2
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of 2,362% compared to the average volume of 165 put options. Xenon Pharmaceuticals Price Performance Shares of Xenon Pharmaceuticals stock opened at $56.69 on Thursday.
fool.com
Mar 27
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
The chief medical officer of Xenon Pharmaceuticals directly sold 1,410 common shares for a transaction value of $78,000 on March 13, 2026. This sale represented 16.63% of his direct common stock holdings prior to the transaction, reducing his direct position from 8,479 to 7,069 shares.
zacks.com
Mar 19
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
defenseworld.net
Mar 17
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Bamco Inc. NY
Bamco Inc. NY reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ: XENE) by 46.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 30,000 shares of the biopharmaceutical company's stock after selling 26,000 shares during the quarter. Bamco Inc. NY's holdings in Xenon
